Distribution · GCC · Announced 3 Dec 2025
Accord Healthcare → Dar Al Dawaa Al Arabiya
Accord Healthcare partnered with UAE-based Dar Al Dawaa Al Arabiya to improve availability of its 37-product oncology portfolio across the UAE; terms were not disclosed.
Parties: Accord Healthcare (United Kingdom) → Dar Al Dawaa Al Arabiya (United Arab Emirates)
- Deal type
- Distribution
- Value
- Undisclosed
- Territory
- United Arab Emirates
- Therapeutic area
- Oncology
- Asset
- Oncology portfolio (37 therapies)
- Announced
- 3 Dec 2025
Our analysis
Why this matters
On 3 December 2025, Accord Healthcare and UAE-based Dar Al Dawaa Al Arabiya announced a strategic partnership to improve access to cancer medicines across the UAE. The deal covers Accord's portfolio of 37 oncology therapies, including core chemotherapy for breast and prostate cancer, treatments for blood disorders and supportive oncology care, with supply through Accord's global supply chain. Biosimilars and newer treatments were also mentioned. No financial terms or duration were disclosed.
For BD directors: generic oncology portfolios are being placed with focused local partners in the Gulf rather than broad-line distributors. Our reading is that hospital tender access is the main prize.
The full analysis is free to read with a work email on this page.
Source: Souq Al Dawaa Saudi